“Long-Term Efficacy and Safety of Lebrikizumab Is Maintained in Patients With Moderate-to-Severe ​ Atopic Dermatitis: Results Up to 3 Years From ADjoin” (2025) SKIN The Journal of Cutaneous Medicine, 9(1), p. s510. doi:10.25251/skin.9.supp.510.